Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Indicator Tracer Agent  > Methylene blue CAS 61-73-4 Methylene Blue anhydrous

Methylene blue CAS 61-73-4 Methylene Blue anhydrous 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand Name: MOSINTER
Molecular formula: C16H18ClN3S
Melting Point: 190 °C (dec.)(lit.)
Flashing point: 45 °C
Colour index (CI): 52015
Production Capacity: 500 Ton/Year
Delivery Date: within 7 days
CAS No.: 61-73-4
Molecular weight: 319.85
Density: 1.0 g/mL at 20 °C
Storage condition: Store at RT
Soluble: 40 g/L (20 ºC)

Methylene blue is a component of a frequently prescribed urinary analgesic/anti-infective/anti-spasmodic

Methylene blue (CAS: 61-73-4)





Brown powder

Melting point ℃




Flash point ℃


Methylene blue (CI 52015) is a heterocyclic aromatic chemical compound with the molecular formula C16H18N3SCl. It has many uses in a range of different fields, such as biology and chemistry. At room temperature it appears as a solid, odorless, dark green powder, that yields a blue solution when dissolved in water. The hydrated form has 3 molecules of water per molecule of methylene blue. Methylene blue should not be confused with methyl blue, another histology stain, new methylene blue, nor with the methyl violets often used as pH indicators.

As an experimental pharmaceutical drug, the International Nonproprietary Name (INN) of methylene blue is methylthioninium chloride.

Methylene blue was first prepared in 1876 by German chemist Heinrich Caro (1834-1910). It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.


Methylene blue was identified by Paul Ehrlich about 1891 as a successful treatment for malaria. It disappeared as an anti-malarial during the Pacific War in the tropics, since American and Allied soldiers disliked its two prominent, but reversible side effects: turning the urine green, and the sclera(the whites of the eyes) blue. Interest in its use as an anti-malarial has recently been revived, especially due to its low price. Several clinical trials are in progress, trying to find a suitable drug combination. Initial attempts to combine methylene blue with chloroquine were disappointing; however, more recent attempts have appeared more promising.


Recent research suggests that methylene blue, toluidine blue, and other 3,7-diaminophenothiazinium-based redox cyclers induce selective cancer cell apoptosis by NAD(P)H:quinone oxidoreductase (NQO1)-dependent bioreductive generation of cellular oxidative stress. Combined with plant auxin (indole-3-acetic acid), methylene blue is being investigated for the photodynamic treatmentof cancer.

Combined with light

Methylene blue combined with light has been used to treat resistant plaque psoriasis, AIDS-related Kaposi's sarcoma, West Nile virus, and to inactivate staphylococcus aureus, HIV-1, Duck hepatitis B, adenovirus vectors, and hepatitis C. Phenothiazine dyes and light have been known to have virucidal properties for over 80 years. In some circumstances, the combination can cause DNA damage that may lead to cancer.

Carbon monoxide poisoning

Methylene blue was also used in the mid-twentieth century in the treatment of carbon monoxide poisoning.

Ifosfamide neurotoxicity

Another, less well-known use of methylene blue is its utility for treating ifosfamide neurotoxicity. Methylene blue was first reported for treatment and prophylaxis of ifosfamide neuropsychiatric toxicity in 1994. A toxic metabolite of ifosfamide, chloroacetaldehyde (CAA), disrupts the mitochondrial respiratory chain, leading to an accumulation of nicotinamide adenine dinucleotide hydrogen (NADH). Methylene blue acts as an alternative electron acceptor, and reverses the NADH inhibition of hepatic gluconeogenesis while also inhibiting the transformation of chloroethylamine into chloroacetaldehyde, and inhibits multiple amine oxidase activities, preventing the formation of CAA. The dosing of methylene blue for treatment of ifosfamide neurotoxicity varies, depending upon its use simultaneously as an adjuvant in ifosfamide infusion, versus its use to reverse psychiatric symptoms that manifest after completion of an ifosfamide infusion. Reports suggest that methylene blue at 50–60 mg up to six doses a day have resulted in improvement of symptoms within 10 minutes to several days. Alternatively, it has been suggested that intravenous methylene blue 50 mg every six hours for prophylaxis during ifosfamide treatment in patients with history of ifosfamide neuropsychiatric toxicity. Prophylactic administration of 50 mg of methylene blue the day before initiation of ifosfamide, and 50 mg three times daily during ifosfamide chemotherapy has been recommended to lower the occurrence of ifosfamide neurotoxicity.

Vasoplegic syndrome after cardiac surgery

Some literature has reported the use of methylene blue as an adjunct in the management of patients experiencing vasoplegic syndrome after cardiac surgery.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: